drugset / Trial / NCT07072884
GC012F in Patients With Autoimmune Diseases
Phase 0
Not yet recruiting
15 enrolled
Qiong Fu
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is an open-label, early exploratory main clinical study to evaluate the safety and efficacy of GC012F Injection in subjects with autoimmune diseases (AID), as well as to assess its pharmacokinetic (PK) and pharmacodynamic (PD) profiles.
Timeline
- Start
- 2025-08-18
- Primary completion
- 2027-03-31
- Completion
- 2029-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 100000 cells/kg | Other |
| Subject | GC012F | Cell therapy | 200000 cells/kg | Other |
| Subject | GC012F | Cell therapy | 300000 cells/kg | Other |